4P7E

Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634

Summary for 4P7E

• Entry DOI: 10.2210/pdb4p7e/pdb
• Descriptor: Tyrosine-protein kinase JAK2, N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide (3 entities in total)
• Functional Keywords: transferase, jak1 inhibitor, triazolopyridine
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 70035.77

Authors

Menet, C.C.J.,Fletcher, S.,Van Lommen, G.,Geney, R.,Blanc, J.,Smits, K.,Jouannigot, N.,van der Aar, E.M.,Clement-Lacroix, P.,Lepescheux, L.,Galien, R.,Vayssiere, B.,Nelles, L.,Christophe, T.,Brys, R.,Uhring, M.,Ciesielski, F.,Van Rompaey, L. (deposition date: 2014-03-27, release date: 2014-11-19, Last modification date: 2024-10-09)

Primary citation

Menet, C.J.,Fletcher, S.R.,Van Lommen, G.,Geney, R.,Blanc, J.,Smits, K.,Jouannigot, N.,Deprez, P.,van der Aar, E.M.,Clement-Lacroix, P.,Lepescheux, L.,Galien, R.,Vayssiere, B.,Nelles, L.,Christophe, T.,Brys, R.,Uhring, M.,Ciesielski, F.,Van Rompaey, L.
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.
J.Med.Chem., 57:9323-9342, 2014

PubMed Abstract: Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).

PubMed: 25369270
DOI: 10.1021/jm501262q

Experimental method

X-RAY DIFFRACTION (2.4 Å)